patent/WO-2019087163-A1

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
filingDate	2018-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc2cd69930a44dfd5d8143d0dbf6e112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_017c501178decfd83862904ed5ec4b7c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcfae419296aba8203c94e6326f818ee
publicationDate	2019-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	WO-2019087163-A1
titleOfInvention	Polycyclic herg activators
abstract	The present invention provides a compound of formula (I), in which R 1 , R 2 , X and R 3 are defined in the summary of the invention, or a pharmaceutically acceptable salt thereof Formula (I); a method for manufacturing the compounds of the invention, and its therapeutic uses linked to the hERG activation. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
priorityDate	2017-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004078163-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015161052-A1
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467579676

Total number of triples: 19.